Kris Cameron Wood

Assistant Professor of Pharmacology & Cancer Biology

Appointments and Affiliations

• Assistant Professor of Pharmacology & Cancer Biology
• Assistant Professor of Biomedical Engineering
• Core Faculty in Innovation & Entrepreneurship
• Member of the Duke Cancer Institute

Contact Information

• Email Address: kris.wood@duke.edu
• Websites:
  • Wood Lab

Education

• Ph.D. Massachusetts Institute of Technology, 2007
• B.S. University of Kentucky at Lexington, 2002

Research Interests

More effective anticancer therapeutic strategies, many of which are based on functional genomics. Examples of projects include: a miniaturized screening platform, tools to systematically map the signaling pathways controlling anticancer drug responses, high-throughput computational methods to discover anticancer drug combinations, design of therapeutic strategies to reverse or prevent drug resistance, and systematic credentialing of mutations uncovered through cancer genome sequencing projects.

Courses Taught

• BIOLOGY 728E: University Program in Genetics and Genomics Biological Solutions Module V
• CMB 710D: Cell & Molecular Biology Module IV
• CMB 778E: University Program in Genetics and Genomics Biological Solutions Module V
• MGM 778E: University Program in Genetics and Genomics Biological Solutions Module V
• MOLCAN 780: Graduate Student Seminar
• MOLCAN 818: Molecular Mechanisms of Oncogenesis
• PHARM 393: Research Independent Study
• PHARM 394: Research Independent Study
• PHARM 493: Research Independent Study
• PHARM 494: Research Independent Study
• PHARM 780S: Graduate Student Seminar
• PHARM 818: Molecular Mechanisms of Oncogenesis
• UPGEN 778E: University Program in Genetics and Genomics Biological Solutions Module V

In the News

• From Innovation to Impact (Oct 3, 2018 | Duke Med Alumni News)
• Faculty Startup Sold to Belgian Pharma for $30 Million (Apr 9, 2018)
• Why Do Perfectly Good Cancer Treatments Suddenly Stop Working? (Oct 25, 2017 | Duke Cancer Institute)
• The Challenges of Combating Cancer Drug Resistance (Nov 19, 2015 | Duke Research Blog)
• Researchers Map Paths to Cancer Drug Resistance (Jan 5, 2015)

Representative Publications

• Ding, Y; Gong, C; Huang, D; Chen, R; Sui, P; Lin, KH; Liang, G; Yuan, L; Xiang, H; Chen, J; Yin, T; Alexander, PB; Wang, Q-F; Song, E-W; Li, Q-J; Wood, KC; Wang, X-F, Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers., Nature Communications, vol 9 no. 1 (2018) [10.1038/s41467-018-06651-x] [abs].
• Soderquist, RS; Crawford, L; Liu, E; Lu, M; Agarwal, A; Anderson, GR; Lin, KH; Winter, PS; Cakir, M; Wood, KC, Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity., Nature Communications, vol 9 no. 1 (2018) [10.1038/s41467-018-05815-z] [abs].
• Ohiri, KA; Kelly, ST; Motschman, JD; Lin, KH; Wood, KC; Yellen, BB, An acoustofluidic trap and transfer approach for organizing a high density single cell array., Lab on a Chip, vol 18 no. 14 (2018), pp. 2124-2133 [10.1039/c8lc00196k] [abs].
• Winter, PS; Wood, KC, Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers., Trends in Cancer, vol 4 no. 5 (2018), pp. 333-335 [10.1016/j.trecan.2018.02.004] [abs].
• Anderson, GR; Wardell, SE; Cakir, M; Yip, C; Ahn, Y-R; Ali, M; Yllanes, AP; Chao, CA; McDonnell, DP; Wood, KC, Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors., Nature Communications, vol 9 no. 1 (2018) [10.1038/s41467-018-04033-x] [abs].